Articles about Bharat Biotech

Centre denies asking Bharat Biotech to address WHO's COVAXIN suspension

29 Apr 2022

India
Centre denies asking Bharat Biotech to address WHO's COVAXIN suspension

The Ministry of External Affairs (MEA) on Friday denied reports that it had asked Bharat Biotech to address issues to avoid the cancellation of the World Health Organization's (WHO) emergency approval for its COVAXIN.

COVAXIN likely to get approval for children above 2yrs: Report

22 Apr 2022

India
COVAXIN likely to get approval for children above 2yrs: Report

Bharat Biotech's COVID-19 vaccine, COVAXIN, is likely to get the Drugs Controller General of India's (DCGI) nod for use among children aged two to 12 years.

COVAXIN supply to be increased as teens get COVID-19 vaccines

03 Jan 2022

India
COVAXIN supply to be increased as teens get COVID-19 vaccines

Pharmaceutical firm Bharat Biotech on Monday said it plans to increase the supply of its COVID-19 vaccine COVAXIN to up to eight crore doses a month, starting February.

Are Indian vaccines effective against Omicron? Here's what manufacturers say

01 Dec 2021

India
Are Indian vaccines effective against Omicron? Here's what manufacturers say

The COVID-19 vaccine manufacturers in India are reportedly waiting for "more data" on the new coronavirus variant, Omicron, to assess the efficacy of their vaccines.

COVAXIN gets WHO approval for emergency use listing

03 Nov 2021

India
COVAXIN gets WHO approval for emergency use listing

The World Health Organization (WHO) on Wednesday granted Emergency Use Listing (EUL) to COVAXIN.

Australia accepts COVAXIN as 'recognized' vaccine for incoming travelers

01 Nov 2021

World
Australia accepts COVAXIN as 'recognized' vaccine for incoming travelers

Australia on Monday accepted India's indigenous vaccine, COVAXIN, as a "recognized" vaccine for the purpose of travel to the country.

Cannot cut corners, thorough evaluation needed for COVAXIN EUL: WHO

19 Oct 2021

India
Cannot cut corners, thorough evaluation needed for COVAXIN EUL: WHO

The World Health Organization (WHO) Monday clarified the reason behind the delay in COVAXIN's emergency use listing (EUL), stating that it is expecting more information from Bharat Biotech on its COVID-19 vaccine.

COVAXIN recommended by expert panel for children aged 2-18 years

12 Oct 2021

India
COVAXIN recommended by expert panel for children aged 2-18 years

The Subject Expert Committee (SEC) on COVID-19 has recommended the approval of Bharat Biotech's COVAXIN for children aged between two and 18 years.

COVAXIN trial data for children aged 2-18 submitted to DCGI

03 Oct 2021

India
COVAXIN trial data for children aged 2-18 submitted to DCGI

Bharat Biotech has reportedly submitted trial data of its COVID-19 vaccine, COVAXIN, for children aged under 18 years to the Drugs and Comptroller General of India (DCGI).

Decision on EUL of COVAXIN in October, says WHO

30 Sep 2021

India
Decision on EUL of COVAXIN in October, says WHO

A decision on Bharat Biotech's submission seeking emergency use listing (EUL) for its COVID-19 vaccine COVAXIN will be made in October, the World Health Organization has said.

COVAXIN for children: Bharat Biotech completes Phase 2/3 trials

21 Sep 2021

India
COVAXIN for children: Bharat Biotech completes Phase 2/3 trials

Bharat Biotech has completed the Phase 2/3 trials of COVID-19 vaccine, COVAXIN for use in children under 18 years of age and is expected to submit the data by next week to the DCGI, Chairman, and Managing Director of Bharat Biotech International Ltd., Krishna Ella said.

Bharat Biotech awaits feedback from WHO for COVAXIN's EUL

17 Sep 2021

India
Bharat Biotech awaits feedback from WHO for COVAXIN's EUL

Bharat Biotech on Friday said it has submitted all the data pertaining to its COVID-19 vaccine COVAXIN to the World Health Organization for EUL and is awaiting feedback from the global health watchdog.

Single COVAXIN dose might be enough for those previously infected

28 Aug 2021

India
Single COVAXIN dose might be enough for those previously infected

A single dose of Bharat Biotech's COVAXIN in previously COVID-19-infected individuals elicits a similar antibody response as obtained with two doses of the vaccine in those without a previous history of the disease, according to an ICMR study.

Bharat Biotech ends its Brazil agreement. What went wrong?

24 Jul 2021

India
Bharat Biotech ends its Brazil agreement. What went wrong?

Bharat Biotech on Friday announced the termination its agreement with two foreign firms for the supply of COVAXIN to Brazil.

Bharat Biotech commits to supply 500mn COVAXIN doses to Centre

23 Jul 2021

India
Bharat Biotech commits to supply 500mn COVAXIN doses to Centre

Bharat Biotech on Friday said it has committed to supply over 500 million doses of COVAXIN to the Centre under the countrywide immunization program.

Bharat Biotech enters contract manufacturing deal for COVAXIN drug substance

28 May 2021

India
Bharat Biotech enters contract manufacturing deal for COVAXIN drug substance

Hester Biosciences on Thursday said a memorandum of understanding (MoU) has been signed between Hyderabad-based vaccine maker Bharat Biotech and Gujarat COVID-19 Vaccine Consortium (GCVC) for contract manufacturing the drug substance for COVAXIN.

COVAXIN overall 77.8% effective in Phase-3 trial, says Bharat Biotech

03 Jul 2021

India
COVAXIN overall 77.8% effective in Phase-3 trial, says Bharat Biotech

COVAXIN, the coronavirus vaccine developed by India's Bharat Biotech, is overall 77.8 percent effective, the company said in a statement today, sharing the final analysis of its phase three trial data.

Bharat Biotech denies wrongdoing in $324mn COVAXIN deal with Brazil

30 Jun 2021

Business
Bharat Biotech denies wrongdoing in $324mn COVAXIN deal with Brazil

Hyderabad-based pharmaceutical company Bharat Biotech denied any wrongdoing on its part after Brazil suspended a $324 million contract for doses of its COVID-19 vaccine COVAXIN.

COVAXIN 77.8% effective; government panel reviews Phase III trial data

22 Jun 2021

India
COVAXIN 77.8% effective; government panel reviews Phase III trial data

COVAXIN, the COVID-19 vaccine developed by Bharat Biotech, has been found 77.8% effective against the viral disease, Phase III trial data reportedly revealed.

Calf serum absent in COVAXIN, involved in development, government clarifies

16 Jun 2021

India
Calf serum absent in COVAXIN, involved in development, government clarifies

COVAXIN, the indigenous COVID-19 vaccine produced by Bharat Biotech, does not contain calf serum, the Union Health Ministry clarified on Wednesday.

AIIMS-Delhi begins screening children for COVAXIN clinical trials from today

07 Jun 2021

India
AIIMS-Delhi begins screening children for COVAXIN clinical trials from today

The All India Institute of Medical Sciences (AIIMS), Delhi will begin screening children from Monday to conduct clinical trials of the indigenously developed, Bharat Biotech's vaccine against COVID-19, COVAXIN.

Health Ministry thrashes reports about 'missing' COVAXIN doses

29 May 2021

India
Health Ministry thrashes reports about 'missing' COVAXIN doses

The Health Ministry has slammed news about unaccounted COVAXIN doses as "unfound media reports" adding that these reports are incorrect and not supported by full information on the matter.

Centre creating 'artificial scarcity' of COVID-19 vaccines: AAP

28 May 2021

Politics
Centre creating 'artificial scarcity' of COVID-19 vaccines: AAP

The AAP on Friday alleged that the Centre is creating artificial scarcity of COVID-19 vaccines to benefit Bharat Biotech and Serum Institute of India, a charge termed by the Delhi BJP as unfounded.

Need more information to give EUL to COVAXIN: WHO

25 May 2021

World
Need more information to give EUL to COVAXIN: WHO

The World Health Organization (WHO) has said that more information is required from Bharat Biotech, which is seeking emergency use listing (EUL) for its COVID-19 vaccine COVAXIN.

COVAXIN trials on children are expected to begin in June

24 May 2021

India
COVAXIN trials on children are expected to begin in June

Bharat Biotech, the pharmaceutical firm behind India's first indigenous COVID-19 vaccine COVAXIN, may begin trials on children in June and is expecting to receive the license in the third quarter of this year.

Bharat Biotech to increase COVAXIN production by 200 million doses

21 May 2021

India
Bharat Biotech to increase COVAXIN production by 200 million doses

Hyderabad-based firm Bharat Biotech has said it will scale up the manufacturing capacity of its coronavirus vaccine, COVAXIN, by an additional 200 million (20 crore) doses per year.

COVAXIN approved for Phase 2/3 trials on 2-18-year-olds

13 May 2021

India
COVAXIN approved for Phase 2/3 trials on 2-18-year-olds

India's apex drug regulator has granted permission for conducting the Phase II/III clinical trial of Bharat Biotech's COVAXIN in the age group of 2 to 18 years, the Union Health Ministry said on Thursday. The trial will be conducted on 525 healthy volunteers.

Government-owned BIBCOL to produce 2 crore COVAXIN doses every month

12 May 2021

India
Government-owned BIBCOL to produce 2 crore COVAXIN doses every month

To accelerate the production of COVAXIN—the indigenous COVID-19 vaccine developed by Hyderabad-based Bharat Biotech—amid severe vaccine shortage in India, the Centre on Wednesday reportedly gave its nod for production of COVAXIN at government-owned Bharat Immunologicals & Biologicals Corporation Limited (BIBCOL) in Uttar Pradesh's Bulandshahr.

COVAXIN phase 2/3 trials for 2-18-year-olds recommended by expert panel

12 May 2021

India
COVAXIN phase 2/3 trials for 2-18-year-olds recommended by expert panel

In a bid to extend the country's vaccination drive to include people below 18 years, an expert panel on Tuesday recommended Hyderabad-based Bharat Biotech's COVID-19 vaccine COVAXIN for phase 2/3 clinical trials on children and adolescents aged two to 18 years.

Truck laden with COVAXIN abandoned for 12 hours, driver missing

01 May 2021

India
Truck laden with COVAXIN abandoned for 12 hours, driver missing

A truck carrying 2.40 lakh doses of COVAXIN worth Rs. 8 crore was left parked for nearly 12 hours after its driver went missing under mysterious circumstances in Madhya Pradesh's Narsinghpur district.

Bharat Biotech reduces COVAXIN price to Rs. 400 for states

29 Apr 2021

India
Bharat Biotech reduces COVAXIN price to Rs. 400 for states

Hyderabad-based pharmaceutical company Bharat Biotech on Thursday reduced the price of its COVID-19 vaccine, COVAXIN, for state governments.

Bharat Biotech to produce 700 million COVAXIN doses per year

20 Apr 2021

India
Bharat Biotech to produce 700 million COVAXIN doses per year

To support vaccination campaigns in India and across the globe, Bharat Biotech has ramped up the manufacturing capacity of its COVID-19 vaccine, COVAXIN, to 700 million doses per annum, the vaccine maker said on Tuesday.

COVAXIN manufacturing facility fails to meet CGMP standards: Brazilian regulator

31 Mar 2021

India
COVAXIN manufacturing facility fails to meet CGMP standards: Brazilian regulator

The Brazilian health regulator Anvisa denied permission to import Bharat Biotech's COVID-19 vaccine COVAXIN into the country after its authorities found that the plant in which the vaccine is being made did not meet the Current Good Manufacturing Practice requirements.

Nepal gives emergency use approval to Bharat Biotech's COVAXIN

20 Mar 2021

World
Nepal gives emergency use approval to Bharat Biotech's COVAXIN

Nepal's national drug regulatory authority on Saturday granted emergency use approval to Bharat Biotech's COVAXIN, becoming the third country to approve India's indigenously developed COVID-19 vaccine.

COVAXIN Phase-II trial interim data shows better reactogenicity, safety: Lancet

09 Mar 2021

Technology
COVAXIN Phase-II trial interim data shows better reactogenicity, safety: Lancet

COVAXIN, the COVID-19 vaccine developed by Hyderabad-based Bharat Biotech, has shown better reactogenicity and safety, Phase II trial interim data published in The Lancet journal showed.

Delhi HC pulls up Centre for exporting COVID-19 vaccines

04 Mar 2021

India
Delhi HC pulls up Centre for exporting COVID-19 vaccines

The Delhi High Court on Thursday pulled up the central government over restricted COVID-19 vaccinations in India, even as vaccine exports to other nations continue.

COVAXIN 81% effective, offers protection against UK variant: Bharat Biotech

03 Mar 2021

Technology
COVAXIN 81% effective, offers protection against UK variant: Bharat Biotech

COVAXIN, the COVID-19 vaccine developed by Hyderabad-based Bharat Biotech, has been found to have 81% interim efficacy against preventing infections, the company said on Wednesday.

A year into pandemic, India's death toll drops to fourth-highest

30 Jan 2021

India
A year into pandemic, India's death toll drops to fourth-highest

As India's battle against coronavirus logged one year on Saturday, the nation slipped on the death toll index, going from the third to fourth position.

COVAXIN may neutralize UK strain of COVID-19: Review report

27 Jan 2021

Technology
COVAXIN may neutralize UK strain of COVID-19: Review report

COVAXIN, developed by Bharat Biotech, has the ability to neutralize the UK variant of the coronavirus, according to a pre-print review by bioRxiv, a free online archive and distribution service for unpublished pre-prints in the life sciences.

Diplomats, including from Pakistan and China, offered coronavirus vaccines

26 Jan 2021

India
Diplomats, including from Pakistan and China, offered coronavirus vaccines

After starting its vaccination drive on January 16, New Delhi has offered made-in-India vaccines to diplomatic corps, including to those from Pakistan and China.

Prev
1 2
Next